scholarly journals 378MO EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%

2020 ◽  
Vol 31 ◽  
pp. S1388
Author(s):  
A. Sezer ◽  
S. Kilickap ◽  
M. Gümüş ◽  
I. Bondarenko ◽  
M. Özgüroğlu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
First Line ◽  
Doublet Chemotherapy ◽  
Platinum Doublet

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study

Lung Cancer ◽  
2015 ◽  
Vol 90 (3) ◽  
pp. 427-432 ◽  
Author(s):  
Denis Moro-Sibilot ◽  
Egbert Smit ◽  
Javier de Castro Carpeño ◽  
Krzysztof Lesniewski-Kmak ◽  
Joachim G. Aerts ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
Doublet Chemotherapy ◽  
Platinum Doublet
Sign in / Sign up

Export Citation Format

Share Document